From: Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma
Patient | Age/sex | Affected eye | CNS disease | Systemic treatment | PVRL location | Initial VA | Final VA | Total # MTX | Time to response (months) | Time to relapse (months) | PVRL status at final FU | Total FU (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 57/F | OD | Frontal lobe DLBCL s/p resection | MTX, RIT | VIT | 20/20 | 20/50 | 4 | 0.25 | – | CR | 33 |
OS | VIT/SR | 20/30 | 20/70 | 9** | 0.25 | 14 | CR | 33 | ||||
2 | 72/F | OS | CNS DLBCL | MTX | VIT/SR | 20/1000 | 20/40 | 8 | 2.0 | – | PR | 20 |
3 | 69/F | OS | R Parietal DLBCL | MTX | VIT | 20/60 | 20/30 | 5* | 1.6 | 5 | CR | 19 |
4 | 66/F | OS | R cerebellar DLBCL | MTX, RIT, TMZ | SR | 20/60 | 20/40 | 1 | 1.2 | – | CR | 14 |
5 | 58/F | OD | Frontal lobe DLBCL | MTX | VIT | 20/25 | 20/20 | 3 | 2.8 | – | CR | 3 |
OS | SR | 20/20 | 20/20 | 3 | 4.2 | – | CR | 4 | ||||
6 | 86/F | OS | None | None | SR | 20/20 | 20/40 | 2 | 2.8 | – | CR | 49 |
7 | 84/M | OD | DLBCL | MTX | SR | 20/70 | 20/150 | 10* | 2.6 | 2.6 | PR | 44 |
OS | VIT/SR†,‡ | 20/30 | 20/50 | 6* | 1.1 | 3.9 | CR | 44 |